Abstracts tagged "Malignancy and rheumatic disease"

Abstract Number: 238 • 2018 ACR/ARHP Annual Meeting
IL Inhibitors Therapy in Rheumatic Diseases and the Risk of Malignancies: Systematic Review and Meta-Analysis of Rare Harmful Effects in Randomized Controlled Trials
Jawad Bilal¹, Irbaz Bin Riaz², Adam Berlinberg³, Abdullah Alhifany⁴, Gilbert Ortega⁵ and Warda Faridi⁶, ¹University of Arizona, Tucson, AZ, ²Mayo Clinic, Richestor, MN, ³Department of Internal Medicine, University of Arizona, Tucson, AZ, ⁴Department of Pharmacy, University of Arizona, Tucson, AZ, ⁵Internal Medicine, University of Arizona, Tucson, Tucson, AZ, ⁶Department of Hematology/Oncology, University of Arizona, Tucson, AZ
Background/Purpose: Tumor necrosis factor alpha (TNFα) inhibitor therapy in patients with rheumatologic disorders is well known to increase the risk of malignancy. While the individual…
Abstract Number: 99 • 2012 ACR/ARHP Annual Meeting
Cancer Iincidence and Type of Malignancy in Rrheumatologic Ddiseases in Korea: Head-to-Head Comparison
Sung Hae Chang¹, Jin Kyun Park² and Eun Bong Lee¹, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Cancer Incidence in Rheumatic Diseases: Head-to-Head Comparison. Background/Purpose: Rheumatic diseases (RD) are associated with increased risk of developing cancer. However, it remains to define, if…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].